Biotechnology News and Research

RSS

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

17 Dec 2009

Avecia Biologics to be acquired by Merck

Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.

17 Dec 2009

New Tandem fund of $300 million presents financing option for Canada’s biotechnology industry

The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada’s biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.

17 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Resorbable Orthopedics makes progress in productization of its patented orthopedic bone void fillers

Wound Management Technologies, Inc. a rapidly growing provider of specialty medical products, announced today that its Resorbable Orthopedics operating subsidiary is moving toward productization of its patented orthopedic bone void fillers. The company currently anticipates products to be introduced in Q3 2010, to the bio-products market, estimated to be a multi-billion dollar international market.

17 Dec 2009

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

Silence Therapeutics and Intradigm merge to form RNAi

The Boards of Silence Therapeutics plc and Intradigm Corporation are delighted to announce the merger of their businesses to form a leading company in the field of RNAi (RNA interference).

17 Dec 2009

Survey examines disease R&D investment in 2008

According to an annual survey released Tuesday by the George Institute for International Health that looks at research and development (R&D) funding of diseases that affect the developing world, the U.S. government in 2008 "remained the single biggest contributor as it again provided almost half of the total funding but the report notes developing countries like Brazil [and] India ... were becoming a growing force," AAP/Sydney Morning Herald reports (Rose, 12/15).

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Genes work together by huddling in clusters inside nucleus, research reveals

Research from the Babraham Institute has revealed for the first time that genes work together by huddling in clusters inside the nucleus - the information centre of a cell. These findings, published in the online edition of the journal Nature Genetics, represent a paradigm shift in our understanding of how the genome is spatially organised in relation to gene expression.

16 Dec 2009

ProtoKinetix evaluates major European proposals to expand AAGP technology use

ProtoKinetix Inc. (PKTX) has been approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas.

16 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).

16 Dec 2009

Biotechnology News and Research

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Avecia Biologics to be acquired by Merck

New Tandem fund of $300 million presents financing option for Canada’s biotechnology industry

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Resorbable Orthopedics makes progress in productization of its patented orthopedic bone void fillers

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

FDA Advisory Committee votes against the approval of Tarceva

Silence Therapeutics and Intradigm merge to form RNAi

Survey examines disease R&D investment in 2008

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Genes work together by huddling in clusters inside nucleus, research reveals

ProtoKinetix evaluates major European proposals to expand AAGP technology use

ThromboGenics completes enrollment in second microplasmin Phase III trial

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Nitric oxide opens up new treatment option for septic shock

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Biotechnology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News